This week, San Diego-based company Biolinq raked in $58 million in a funding round led by Alpha Wave Ventures, bringing its total funding to date to $178 million.
The company, founded in 2012, is developing…
Continue Reading
What You Should Know: – Biolinq, a provider of precision wearable biosensors for metabolic health secures $58M led by Alpha Wave Ventures. The round will include participation from Niterra’s corporate venture capital fund jointly…
Continue Reading
What You Should Know:
– Ultrahuman, a pioneer in wearable health technology raises $35M in Series B funding led by prominent like Blume Ventures and Steadview Capital.
– Ultrahuman is set to achieve a significant milestone…
Continue Reading
Type 1 diabetes (T1D) is a chronic condition characterized by glucose fluctuations. Laboratory studies suggest that cognition is reduced when glucose is very low (hypoglycemia) and very high (hyperglycemia). Until recently, technological limitations prevented…
Continue Reading
An over-the-counter continuous glucose monitoring (CGM) solution developed by Dexcom called Stelo has received clearance from the Food and Drug Administration (FDA).Available without the need for a prescription, the wearable biosensor boasts a battery…
Continue Reading
What You Should Know:
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t…
Continue Reading
What You Should Know: – Know Labs (NYSE American: KNW), a leading innovator in non-invasive medical diagnostic technology, today announced the unveiling of its KnowU™, a wearable, non-invasive continuous glucose monitor (CGM). – With…
Continue Reading
Medicare’s April 2023 decision to increase coverage for continuous glucose monitoring (CGM) was a major development for diabetes management. Now, with over a million new eligible beneficiaries and many more to follow this year,…
Continue Reading
What You Should Know:
– Medicare has significantly expanded access to the Eversense E3 continuous glucose monitoring (CGM) System, a long-lasting and implantable option that offers several advantages over traditional CGMs.
– Medicare has significantly expanded…
Continue Reading
What You Should Know:
– Tandem Diabetes Care and Abbott have joined forces to bring the first automated insulin delivery (AID) system in the US compatible with Abbott’s latest FreeStyle Libre 2 Plus sensor.
– The…
Continue Reading
